Show simple item record

dc.contributor.authorCalifano, Raffaele
dc.contributor.authorRomanidou, O
dc.contributor.authorMountzios, G
dc.contributor.authorLandi, L
dc.contributor.authorCappuzzo, F
dc.contributor.authorBlackhall, Fiona H
dc.date.accessioned2016-05-25T15:27:09Zen
dc.date.available2016-05-25T15:27:09Zen
dc.date.issued2016-04-29en
dc.identifier.citationManagement of NSCLC disease progression after first-line EGFR tyrosine kinase inhibitors: what are the issues and potential therapies? 2016: Drugsen
dc.identifier.issn0012-6667en
dc.identifier.pmid27129321en
dc.identifier.doi10.1007/s40265-016-0578-zen
dc.identifier.urihttp://hdl.handle.net/10541/610744en
dc.description.abstractEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for advanced non-small cell lung cancer (NSCLC) patients whose tumor harbors an activating EGFR mutation. The vast majority of patients will experience disease control with an EGFR-TKI but inevitably all patients will progress, often within a year of treatment. There is no current standard of care for this scenario but, in clinical practice, most of the patients will be offered platinum-based doublet chemotherapy. In some situations, continuation of the EGFR-TKI beyond radiological progression, with or without use of local treatments in case of oligo-progressive disease, represents a reasonable therapeutic option. The aim of this review is to describe the different treatment strategies that have been developed to tackle progression on EGFR-TKIs, including specific clinical scenarios and novel agents designed to tackle the common T790M resistance mutation.
dc.languageENGen
dc.rightsArchived with thanks to Drugsen
dc.titleManagement of NSCLC disease progression after first-line EGFR tyrosine kinase inhibitors: what are the issues and potential therapies?en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.en
dc.identifier.journalDrugsen
html.description.abstractEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for advanced non-small cell lung cancer (NSCLC) patients whose tumor harbors an activating EGFR mutation. The vast majority of patients will experience disease control with an EGFR-TKI but inevitably all patients will progress, often within a year of treatment. There is no current standard of care for this scenario but, in clinical practice, most of the patients will be offered platinum-based doublet chemotherapy. In some situations, continuation of the EGFR-TKI beyond radiological progression, with or without use of local treatments in case of oligo-progressive disease, represents a reasonable therapeutic option. The aim of this review is to describe the different treatment strategies that have been developed to tackle progression on EGFR-TKIs, including specific clinical scenarios and novel agents designed to tackle the common T790M resistance mutation.


This item appears in the following Collection(s)

Show simple item record